PetMed Express Inc (PETS) (Q2 2027) Earnings Call Highlights: New CEO Charts

PetMed Express (PETS) reported Q2 2027 net sales of $35.8M, down 19.4% YoY, with a net loss of $6.4M. New CEO Jeff Willard highlighted cost reductions, including a 32% drop in customer acquisition cost and a 52.3% cut in advertising expenses. The company has $11.4M in cash and no debt. Willard outlined a multiyear turnaround strategy focusing on brand repositioning, marketing efficiency, and customer retention. Gross margin fell to 27.4% due to product mix and lower rebates.

Original reporting
Published Nov 11, 2026, 9:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 9:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PetMed Express Inc (PETS) (Q2 2027) Earnings Call Highlights: New CEO Charts — source image
Decision brief

The 30-second read

$PETSBearishMed
01

Why it matters

The earnings release provides the first detailed financial snapshot under the new leadership, revealing both operational improvements and revenue headwinds.

02

Market read

First‑time disclosure of Q2 2027 results for PETS, offering fresh data for traders to assess short‑term price direction.

03

What to watch

New white‑label partnerships with Rural King and Pet Supermarket may unlock incremental revenue not reflected in the current quarter.

Relevance 7/10Novelty 8/10Timing: post‑earnings release today

Background

PetMed Express (NASDAQ:PETS) is a specialty online pharmacy for pet medications, recently appointing Jeff Willard as CEO.

Company-level read

Ticker impact

$PETSBearishHigh confidence
Context

Q2 2027 earnings released showing a 19.4% sales decline and a narrowed net loss, with new CEO Jeff Willard outlining a turnaround plan.

Expected impact

likely downward pressure as investors price in weaker sales despite expense cuts

Evidence & confidence

The primary disclosure of a sizable sales drop and loss outweighs the positive cost‑saving headlines, leading to short‑term sell pressure.

Market effects

Highlights challenges in the online pet pharmacy niche, potentially prompting peers to reassess cost structures.

Limited to U.S. small‑cap investors; no broader regional effect.

Minimal global impact; primarily a micro‑cap earnings story.

Counterpoint

Cost cuts and a debt‑free balance sheet could set the stage for a turnaround, making the dip a buying opportunity.

Key entities

  • Jeff Willard

    New CEO with turnaround experience leading the company's strategic shift.

  • Doug Krulik

    Interim Principal Financial Officer who presented the financial results.

Related articles

$PETSMed

PetMed Express (PETS) Q1 2027 Earnings Call Transcript

PetMed Express reported Q1 2027 net sales of $41M, down 19.9% YoY, with a net loss of $6.1M. Key highlights include a $37M sale-leaseback deal, a partnership with Rural King, and an unsolicited acquisition offer of $3 per share. Management emphasized expense management and new revenue channels. Net sales stabilized above $40M sequentially, despite prescription sales declines.

$PETSMedAI 9/10

PetMed Express Inc (PETS) Q4 2026 Earnings Call Highlights: Navigating Challenges and Embracing...

PetMed Express (PETS) reported fiscal 2026 net sales down 21.1% and a full-year net loss of $57.3 million, including $26.7 million goodwill impairment and $2.1 million inventory write-down, plus $4.5 million in non-recurring legal/severance costs tied to a whistleblower probe. The company said it regained regulatory compliance, fixed three material weaknesses, exited underperforming vendors for ~$6.1 million annualized savings, and saw its first Q4 sequential net sales increase since 2024.

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.